{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-010598","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.013566+00:00","generated_at":"2026-05-31T13:51:29.757212+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"NextCure reports Q2 net loss $15.4M; cash $86.4M; LNCB74 IND on track for year-end","bullets":["Net loss $15.4M in Q2 2024 vs $17.9M in Q2 2023; R&D expenses $12.4M (down from $13.4M).","Cash & marketable securities $86.4M as of June 30, 2024; expected to fund operations into H2 2026.","LNCB74 (B7-H4 ADC) GLP tox studies completed; IND submission planned by year-end 2024.","NC410 + pembrolizumab ovarian cohort enrollment completed (16 additional patients); data expected Q4 2024.","NC181 (Alzheimer's) manufacturing initiated for tox studies; seeking partnering/funding for IND mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-010598","json":"https://secwatch.observer/filing/0001558370-24-010598.json","markdown":"https://secwatch.observer/filing/0001558370-24-010598.md","text":"https://secwatch.observer/filing/0001558370-24-010598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000155837024010598/0001558370-24-010598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000155837024010598/nxtc-20240801x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:51:29.757212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}